Trials / Completed
CompletedNCT01258686
Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy
A Double-blind Phase III Study With Silymarin in the Patients Infected With HCV Who Failed Conventional Antiviral Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Bukwang Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effectiveness of silymarin 700 mg thrice daily and assess the safety in patients with hepatitis C virus infection compared to a placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Silymarin | 700mg thrice daily |
| DRUG | Placebo | Placebo 700mg thrice daily |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2012-11-01
- Completion
- 2013-08-01
- First posted
- 2010-12-13
- Last updated
- 2013-11-25
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01258686. Inclusion in this directory is not an endorsement.